Max Hasmann

3.0k total citations · 1 hit paper
49 papers, 2.3k citations indexed

About

Max Hasmann is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Max Hasmann has authored 49 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 24 papers in Radiology, Nuclear Medicine and Imaging and 21 papers in Molecular Biology. Recurrent topics in Max Hasmann's work include HER2/EGFR in Cancer Research (25 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Cell Adhesion Molecules Research (7 papers). Max Hasmann is often cited by papers focused on HER2/EGFR in Cancer Research (25 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Cell Adhesion Molecules Research (7 papers). Max Hasmann collaborates with scholars based in Germany, United Kingdom and Switzerland. Max Hasmann's co-authors include Werner Scheuer, Thomas Friess, Birgit Bossenmaier, Josef Endl, Helmut Burtscher, R. Löser, Benno Rattel, Simon P. Langdon, Katja Wosikowski and Peter Mullen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Max Hasmann

47 papers receiving 2.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.

2003 513 citations Max Hasmann et al. PubMed profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Max Hasmann	1.4k	912	766	364	241	49	2.3k
H. Peter Rodemann	979 0.7×	1.8k 2.0×	358 0.5×	44 0.1×	411 1.7×	56	3.0k
Ivana Sarotto	885 0.6×	808 0.9×	576 0.8×	240 0.7×	86 0.4×	50	2.3k
Ali R. Jazirehi	915 0.7×	1.4k 1.5×	362 0.5×	115 0.3×	90 0.4×	63	2.7k
Kirsteen H. Maclean	1.1k 0.8×	2.6k 2.9×	127 0.2×	67 0.2×	684 2.8×	30	3.6k
Mahmoud Toulany	1.1k 0.8×	1.9k 2.1×	236 0.3×	31 0.1×	254 1.1×	59	3.0k
Kwang Woon Kim	596 0.4×	1.2k 1.3×	70 0.1×	84 0.2×	608 2.5×	32	1.8k
Xuanmao Jiao	1.3k 1.0×	1.8k 2.0×	90 0.1×	125 0.3×	136 0.6×	58	3.0k
Carolyn Cao	709 0.5×	1.3k 1.4×	103 0.1×	52 0.1×	356 1.5×	30	1.9k
Ana M. Tari	708 0.5×	1.7k 1.9×	238 0.3×	31 0.1×	172 0.7×	65	2.6k
Masahiko Nishiyama	1.3k 1.0×	1.6k 1.8×	152 0.2×	51 0.1×	202 0.8×	188	3.3k

Countries citing papers authored by Max Hasmann

Since Specialization

Citations

This map shows the geographic impact of Max Hasmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Hasmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Hasmann more than expected).

Fields of papers citing papers by Max Hasmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Hasmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Hasmann. The network helps show where Max Hasmann may publish in the future.

Co-authorship network of co-authors of Max Hasmann

This figure shows the co-authorship network connecting the top 25 collaborators of Max Hasmann. A scholar is included among the top collaborators of Max Hasmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Hasmann. Max Hasmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Berdiel‐Acer, Mireia, Eileen Reinz, Johanna Sonntag, et al.. (2022). Disentangling ERBB Signaling in Breast Cancer Subtypes—A Model-Based Analysis. Cancers. 14(10). 2379–2379. 3 indexed citations

Cejalvo, Juan Miguel, Wolfgang Jacob, Tania Fleitas, et al.. (2019). A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open. 4(4). e000532–e000532. 22 indexed citations

Moisan, Annie, Francesca Michielin, Wolfgang Jacob, et al.. (2018). Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy. Molecular Cancer Therapeutics. 17(7). 1464–1474. 18 indexed citations

Jacob, Wolfgang, Ian James, Max Hasmann, & Maja Weisser. (2018). Clinical development of HER3-targeting monoclonal antibodies: Perils and progress. Cancer Treatment Reviews. 68. 111–123. 43 indexed citations

Wartha, Katharina, Frank Herting, & Max Hasmann. (2014). Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation. Pharmacology & Therapeutics. 142(3). 351–361. 28 indexed citations

De, Pradip, Max Hasmann, & Brian Leyland‐Jones. (2013). Molecular determinants of trastuzumab efficacy: What is their clinical relevance?. Cancer Treatment Reviews. 39(8). 925–934. 53 indexed citations

Bartsch, Rupert, S. Frings, Ahmad Awada, et al.. (2013). Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. Annals of Oncology. 25(4). 773–780. 7 indexed citations

Bertelsen, Vibeke, et al.. (2013). Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. Carcinogenesis. 34(9). 2031–2038. 23 indexed citations

Mamidi, Srinivas, et al.. (2013). Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab. Molecular Oncology. 7(3). 580–594. 89 indexed citations

10.

Thomas, Marlène, R Korn, Gero Brockhoff, et al.. (2013). Detection of Truncated HER2 Forms in Formalin-Fixed, Paraffin-Embedded Breast Cancer Tissue Captures Heterogeneity and Is Not Affected by HER2-Targeted Therapy. American Journal Of Pathology. 183(2). 336–343. 7 indexed citations

11.

Sims, Andrew H., Annelien J.M. Zweemer, Yoko Nagumo, et al.. (2012). Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. British Journal of Cancer. 106(11). 1779–1789. 38 indexed citations

12.

Faratian, Dana, Annelien J.M. Zweemer, Yoko Nagumo, et al.. (2011). Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies. Clinical Cancer Research. 17(13). 4451–4461. 44 indexed citations

13.

Scheuer, Werner, Thomas Friess, Helmut Burtscher, et al.. (2009). Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models. Cancer Research. 69(24). 9330–9336. 460 indexed citations

14.

Friess, Thomas, Werner Scheuer, & Max Hasmann. (2007). Combinations of trastuzumab with either pertuzumab or bevacizumab show higher efficacy than lapatinib-based combinations against HER2-positive breast cancer xenografts progressing on trastuzumab monotherapy. Molecular Cancer Therapeutics. 6.

15.

Mullen, Peter, David Cameron, Max Hasmann, John F. Smyth, & Simon P. Langdon. (2007). Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Molecular Cancer Therapeutics. 6(1). 93–100. 50 indexed citations

16.

Friess, Thomas, Werner Scheuer, & Max Hasmann. (2006). Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.. PubMed. 26(5A). 3505–12. 14 indexed citations

17.

Stoetzer, Oliver J., et al.. (2002). Modulation of apoptosis by mitochondrial uncouplers: apoptosis-delaying features despite intrinsic cytotoxicity. Biochemical Pharmacology. 63(3). 471–483. 21 indexed citations

18.

Seidel, André, et al.. (1995). Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 426(3). 249–56. 42 indexed citations

19.

Wosikowski, Katja, Willy Küng, Max Hasmann, R. Löser, & Urs Eppenberger. (1993). Inhibition of growth‐factor‐activated proliferation by anti‐estrogens and effects on early gene expression of mcf‐7 cells. International Journal of Cancer. 53(2). 290–297. 40 indexed citations

20.

Hasmann, Max, et al.. (1989). Membrane potential differences between adriamycin-sensitive and -resistant cells as measured by flow cytometry. Biochemical Pharmacology. 38(2). 305–312. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact